158 related articles for article (PubMed ID: 7138618)
21. [Effect of fibrinogen, fibrin and fibrin (ogen) degradation products on the tissue plasminogen activator and plasminogen activator inhibitor-1 expressions of vascular endothelial cells in coculture system].
Cao YJ; Wu YH; Liu CF
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Jan; 36(1):62-7. PubMed ID: 19099932
[TBL] [Abstract][Full Text] [Related]
22. [Clinical significance of a new fibrinogen/fibrin degradation products(FDP) test using plasma samples for the diagnosis of fibrinogenolysis and fibrinolysis].
Imoto K; Yasumuro Y; Taki M; Suzuki N; Tanabe H; Ichikawa Y
Rinsho Byori; 2001 Mar; 49(3):283-9. PubMed ID: 11307330
[TBL] [Abstract][Full Text] [Related]
23. Urokinase plasminogen activator released by alveolar epithelial cells modulates alveolar epithelial repair in vitro.
Van Leer C; Stutz M; Haeberli A; Geiser T
Thromb Haemost; 2005 Dec; 94(6):1257-64. PubMed ID: 16411403
[TBL] [Abstract][Full Text] [Related]
24. Fibrinogen, fibrin and the arterial wall.
Smith EB
Eur Heart J; 1995 Mar; 16 Suppl A():11-4; discussion 14-5. PubMed ID: 7796823
[TBL] [Abstract][Full Text] [Related]
25. Fibrin monomer and fibrinopeptide B act additively to increase DNA synthesis in smooth muscle cells cultured from human saphenous vein.
Sturge J; Carey N; Davies AH; Powell JT
J Vasc Surg; 2001 Apr; 33(4):847-53. PubMed ID: 11296341
[TBL] [Abstract][Full Text] [Related]
26. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis.
Smith EB
Clin Haematol; 1986 May; 15(2):355-70. PubMed ID: 3524931
[TBL] [Abstract][Full Text] [Related]
27. [The role of fibrinogen in the pathogenesis of artherosclerosis and the mechanisms of its action].
Wang XQ
Sheng Li Ke Xue Jin Zhan; 1996 Jul; 27(3):245-8. PubMed ID: 9772365
[TBL] [Abstract][Full Text] [Related]
28. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
29. Haemostatic factors and atherogenesis.
Smith EB
Atherosclerosis; 1996 Aug; 124(2):137-43. PubMed ID: 8830927
[TBL] [Abstract][Full Text] [Related]
30. Secretion of fibrinolytic enzymes facilitates human mesenchymal stem cell invasion into fibrin clots.
Neuss S; Schneider RK; Tietze L; Knüchel R; Jahnen-Dechent W
Cells Tissues Organs; 2010; 191(1):36-46. PubMed ID: 19390164
[TBL] [Abstract][Full Text] [Related]
31. Fibrinogen, fibrin, and FDP induce C-reactive protein generation in rat vascular smooth muscle cells: pro-inflammatory effect on atherosclerosis.
Guo F; Liu J; Wang C; Liu N; Lu P
Biochem Biophys Res Commun; 2009 Dec; 390(3):942-6. PubMed ID: 19852936
[TBL] [Abstract][Full Text] [Related]
32. The stimulatory capacity of soluble fibrin prepared from high and low molecular weight fibrinogen on plasminogen activation.
Halvorsen S; Skjønsberg OH; Godal HC
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):133-7. PubMed ID: 8457641
[TBL] [Abstract][Full Text] [Related]
33. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.
Prentice CR; Hampton KK; Grant PJ; Nelson SR; Nieuwenhuizen W; Gaffney PJ
Br J Haematol; 1993 Feb; 83(2):276-81. PubMed ID: 8457476
[TBL] [Abstract][Full Text] [Related]
34. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
Van Geet C; Proesmans W; Arnout J; Vermylen J; Declerck PJ
Kidney Int; 1998 Oct; 54(4):1324-30. PubMed ID: 9767551
[TBL] [Abstract][Full Text] [Related]
35. Fibrin-specific fibrinolysis.
Collen D; Lijnen HR
Ann N Y Acad Sci; 1992 Dec; 667():259-71. PubMed ID: 1285022
[No Abstract] [Full Text] [Related]
36. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor.
McNamara CA; Sarembock IJ; Gimple LW; Fenton JW; Coughlin SR; Owens GK
J Clin Invest; 1993 Jan; 91(1):94-8. PubMed ID: 8380817
[TBL] [Abstract][Full Text] [Related]
37. Role of D and E domains in the migration of vascular smooth muscle cells into fibrin gels.
Kodama M; Naito M; Nomura H; Iguchi A; Thompson WD; Stirk CM; Smith EB
Life Sci; 2002 Jul; 71(10):1139-48. PubMed ID: 12095535
[TBL] [Abstract][Full Text] [Related]
38. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
Eisenberg PR; Jaffe AS; Stump DC; Collen D; Bovill EG
Circulation; 1990 Oct; 82(4):1159-68. PubMed ID: 2119264
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
40. Monitoring activity of fibrinolytic agents. A therapeutic challenge.
Shafer KE; Santoro SA; Sobel BE; Jaffe AS
Am J Med; 1984 May; 76(5):879-86. PubMed ID: 6232847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
